BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23449418)

  • 1. [Development of siRNA delivery strategy by active control of tumor microenvironment].
    Ishida T; Kiwada H
    Yakugaku Zasshi; 2013; 133(3):379-86. PubMed ID: 23449418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.
    Tagami T; Abu Lila AS; Matsunaga M; Moriyoshi N; Nakamura H; Nakamura K; Suzuki T; Doi Y; Ishida T; Kiwada H
    Drug Deliv Transl Res; 2012 Apr; 2(2):77-86. PubMed ID: 25786716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
    Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stealth monoolein-based nanocarriers for delivery of siRNA to cancer cells.
    Oliveira AC; Raemdonck K; Martens T; Rombouts K; Simón-Vázquez R; Botelho C; Lopes I; Lúcio M; González-Fernández Á; Real Oliveira ME; Gomes AC; Braeckmans K
    Acta Biomater; 2015 Oct; 25():216-29. PubMed ID: 26225736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness.
    Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G
    Eur J Pharm Sci; 2016 Oct; 93():493-503. PubMed ID: 27593989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
    Li Y; Liu R; Shi Y; Zhang Z; Zhang X
    Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic siRNA Delivery with a Dual pH-Responsive and Tumor-targeted Nanovector for Inhibiting Tumor Growth and Spontaneous Metastasis in Orthotopic Murine Model of Breast Carcinoma.
    Fan B; Kang L; Chen L; Sun P; Jin M; Wang Q; Bae YH; Huang W; Gao Z
    Theranostics; 2017; 7(2):357-376. PubMed ID: 28042340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production.
    Tagami T; Nakamura K; Shimizu T; Ishida T; Kiwada H
    J Control Release; 2009 Aug; 137(3):234-40. PubMed ID: 19361546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
    Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
    J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS; Yawata T; Honke K
    Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL
    J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.
    Doi Y; Abu Lila AS; Matsumoto H; Okada T; Shimizu T; Ishida T
    Int J Nanomedicine; 2016; 11():5573-5582. PubMed ID: 27822036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
    Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
    Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
    Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
    Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced gene delivery efficiency of cationic liposomes coated with PEGylated hyaluronic acid for anti P-glycoprotein siRNA: a potential candidate for overcoming multi-drug resistance.
    Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Huang K; Chen X; Zhang Z; He Q
    Int J Pharm; 2014 Dec; 477(1-2):590-600. PubMed ID: 25448564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcyclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy.
    Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Fu H; Zhang Z; He Q
    J Pharm Sci; 2015 Feb; 104(2):476-84. PubMed ID: 25256603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
    Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
    Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine-polycarboxybetaine lipid for systemic delivery of siRNA.
    Li Y; Cheng Q; Jiang Q; Huang Y; Liu H; Zhao Y; Cao W; Ma G; Dai F; Liang X; Liang Z; Zhang X
    J Control Release; 2014 Feb; 176():104-14. PubMed ID: 24365128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.